Rhythm Pharmaceuticals, Inc. (RYTM) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R).
Is Rhythm Pharmaceuticals, Inc. stock overvalued or undervalued in 2026?
As of November 3, 2026, Rhythm Pharmaceuticals, Inc. (RYTM) trades at $86.44 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Rhythm Pharmaceuticals, Inc.
Market cap $6B · 52 weeks $76 – $118 (21 % below the high) · P/E no earnings · Dividend none · Next earnings February 25, 2027 · expected EPS -$0.68 · Closing price, Nov 3 · accounts published Nov 3.
- Valuation: P/Sales 23.9× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 4 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 3.0 %, fails.
- Market cap / Cash 14.4×, fails.
- Cash Runway 40 months, passes.
- Total Debt 0.1×, passes.
- Annual cash burn $1.78, info.
Against its peers (reference peers) — Rhythm Pharmaceuticals, Inc.: P/E —; EV/EBITDA —; ROIC -63.9 %; $6.0B. BioMarin Pharmaceutical Inc. (P/E —; EV/EBITDA 31.9×; ROIC -1.0 %; $10.8B), PTC Therapeutics, Inc. (P/E —; EV/EBITDA 29.9×; ROIC 5.7 %; $5.7B), Ligand Pharmaceuticals Incorporated (P/E 140×; EV/EBITDA 93.2×; ROIC 2.3 %; $6.3B).
Profitability
| Return on Equity | -83.68% |
| Return on Invested Capital | -63.91% |
| Return on Assets | -43.74% |
| Gross Margin | 88.23% |
| Operating Margin | -66.70% |
| Net Margin | -69.03% |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 2.78 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 15.89 |
Price Performance
| 1 month | +1.07% |
| 3 months | -16.65% |
| Year-to-date | -12.71% |
| 1 year | -11.00% |
| 3 years | +246.46% |
| 5 years | +572.23% |
Related companies: BMRN · BLTE · VKTX · MBX · SEPN
Explore sector: Healthcare · Biotechnology
More sections of RYTM: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks